liver support system diachysis type therapeutic device assist performing functions liver systems focus either removing accumulating toxins liver dialysis providing additional replacement metabolic functions liver inclusion hepatocytes device bioartificial liver device system trial help people acute liver failure alf acuteonchronic liver primary functions liver include removing toxic substances blood manufacturing blood proteins storing energy form glycogen secreting bile hepatocytes perform tasks killed impaired disease resulting acute liver failure alf seen person previously diseased liver healthy one hyperacute acute liver failure clinical picture develops rapidly progressive encephalopathy multiorgan dysfunction hyperdynamic circulation coagulopathy acute kidney injury respiratory insufficiency severe metabolic alterations cerebral edema lead brain cases mortality without liver transplantation ltx ranges ltx effective treatment patients although requires precise indication timing achieve good results nevertheless due scarcity organs carry liver transplantations estimated one third patients alf die waiting hand patient chronic hepatic disease suffer acute decompensation liver function following precipitating event variceal bleeding sepsis excessive alcohol intake among others lead condition referred acuteonchronic liver failure aclf types hepatic insufficiency alf aclf potentially reversible liver functionality return level similar prior insult precipitating event ltx shown improvement prognosis survival severe cases alf nevertheless cost donor scarcity prompted researchers look new supportive treatments act bridge transplant procedure stabilizing patients clinical state creating right conditions could allow recovery native liver functions detoxification synthesis improve episode alf three different types supportive therapies developed bioartificial artificial hybrid liver support systems table extracorporeal liver assist device molecular adsorbent recirculating system bioartificial liver support system fractionated plasma separation adsorption system tecahybrid artificial liver support system radial flow bioreactor singlepass albumin dialysis modular extracorporeal liver support bioartificial liver selective plasma filtration therapy bioartificial liver devices experimental extracorporeal devices use living cell lines provide detoxification synthesis support failing liver bioartificial liver bal hepatassist uses porcine hepatocytes whereas elad system employs hepatocytes derived human hepatoblastoma cell techniques produce fulminant hepatic failure fhf improvement hepatic encephalopathy grade biochemical parameters potential side effects documented include immunological issues porcine endogenous retrovirus transmission infectious complications tumor transmigration biological hepatic systems bioartificial liver support blss radial flow bioreactor rfb detoxification capacity systems poor therefore must used combined systems mitigate deficiency today use limited centers high experience bioartificial liver device bal artificial extracorporeal liver support els system individual suffering acute liver failure alf acuteonchronic liver failure aclf fundamental difference artificial bal systems lies inclusion hepatocytes reactor often operating alongside purification circuits used artificial els systems overall design varies different bal systems largely follow basic structure patient blood plasma flow artificial matrix housing hepatocytes plasma often separated patient blood improve efficiency system device connected artificial liver dialysis devices order increase effectiveness device filtration toxins inclusion functioning hepatocytes reactor allows restoration synthetic functions patient liver first bioartificial liver device developed dr achilles demetriou cedarssinai medical center bioartificial liver helped southern california woman survive without liver hours received human liver using plastic cylinder filled cellulose fibers pig liver cells blood routed outside patients body artificial liver returned dr kenneth matsumaras work bal led named invention year time magazine liver cells obtained animal used instead developing piece equipment function liver structure function first device also resembles todays bals animal liver cells suspended solution patients blood processed semipermeable membrane allow toxins blood proteins pass restricts immunological advancements bioengineering techniques decade matsumaras work led improved membranes hepatocyte attachment cell sources include primary porcine hepatocytes primary human hepatocytes human hepatoblastoma immortalized human cell lines stem purpose baltype devices permanently replace liver functions serve supportive either allowing liver regenerate properly upon acute liver failure bridge individuals liver functions transplant possible bals essentially bioreactors embedded hepatocytes liver cells perform functions normal liver process oxygenated blood plasma separated blood several types bals developed including hollow fiber systems flat membrane sheet various types hepatocytes used devices porcine hepatocytes often used due ease acquisition cost however relatively unstable carry risk crossspecies disease primary human hepatocytes sourced donor organs present several problems cost difficulty obtain especially current lack transplantable addition questions raised tissue collected patients transmitting malignancy infection via bal device several lines human hepatocytes also used bal devices including tumour cell lines due origin hepatomas possess potential pass malignancy ongoing research cultivation new types human hepatocytes capable improved longevity efficacy bioreactor currently used cell types pose risk transfer malignancy infection hepz cell line created werner et similar kidney dialysis hollow fiber systems employ hollow fiber cartridge hepatocytes suspended gel solution collagen injected series hollow fibers case collagen suspension gelled within fibers usually temperature change hepatocytes contract gel attachment collagen matrix reducing volume suspension creating flow space within fibers nutrient media circulated fibers sustain cells use plasma removed patients blood patients plasma fed space surrounding fibers fibers composed semipermeable membrane facilitate transfer toxins nutrients chemicals blood suspended cells membrane also keeps immune bodies immunoglobulins passing cells prevent immune system currently hollowfibre bioreactors commonly accepted design clinical use due capillarynetwork allowing easy perfusion plasma across cell however structures limitations convectional transport issues nutritional gradients nonuniform seeding inefficient immobilisation cells reduced hepatocyte growth restricting effectiveness bal researchers investigating use cryogels replace hollowfibres cell carrier components bal systems cryogels supermacroporous threedimensional polymers prepared subzero temperatures freezing solution cryogel precursors solvent pores develop freezing process cryogel solution cools solvent begins form crystals causes concentration cryogel precursors solution increase initiating cryogelation process forming polymer walls cryogel warms solvent crystals thaw leaving cavities form cryogel pores range size µm size forming interconnected network mimics capillary system large surface area volume ratio supporting large numbers immobilised cells convection mediated transport also supported cryogels enabling even distribution nutrients metabolite elimination overcoming shortcomings hollowfibre cryogel scaffolds demonstrate good mechanical strength biocompatibility without triggering immune response improving potential longterm inclusion bal devices invitro another advantage cryogels flexibility use variety tasks including separation purification substances along acting extracellular matrix cell growth proliferation immobilisation specific ligands onto cryogels enables adsorption specific substances supporting use treatment options separation haemoglobin localised sustained method drug jain et investigated polyanconvp polynipaamchitosan cryogels hepatocyte carriers bal system found cellseeded bioreactors reduced levels bilirubin ammonia plasma respectively increased level albumin compared control group demonstrated cells bioreactor able carry detoxifying synthetic functions normal liver cells however hours plasma circulation hepatocyte function deteriorated rapidly likely due toxic effect aclf plasma nutrient oxygen depletion damania et took system step utilising seeded polynipaamchitosan cryogels bioreactor along activated charcoal cloth used filter seen artificial bal devices activated charcoal useful filtration liver toxins including ammonia bilirubin researchers incorporated bioreactor rat model connecting rats induced liver failure system passing blood across plasmaseparation membrane plasma running seeded cryogel charcoal filter compared results rats induced liver failure connected bioreactor measuring levels ammonia urea bilirubin albumin ast time period found reduction bilirubin ast urea levels increase albumin levels suggesting bioreactor functioning removal toxins synthesis new proteins addition ran experiment using acellular bioreactor found bilirubin ast decreased time lesser degree seeded bioreactor showing detoxification results seeded reactor due combination cells activated charcoal cloth however cellseeded reactor increase levels ammonia researchers stated could attributed toxins detrimental effect cells time reducing function numerous clinical studies involving hollowfibre bioreactors overall show promise provide statistically significant evidence supporting effectiveness generally due inherent design limitations causing convectional transport issues nutritional gradients nonuniform seeding inefficient immobilisation cells reduced hepatocyte writing cryogelbased devices entered clinical trials however laboratory results hopefully trials begin soon hepatassist developed cedarssinai medical center bal device containing porcine hepatocytes within hollowfibre bioreactor semipermeable fibres act capillaries allowing perfusion plasma device across hepatocytes surrounding fibres system incorporates charcoal column act filter removing additional toxins demetriou et carried large randomised multicentre controlled trial safety efficacy hepatassist device patients alf stemming viral hepatitis paracetamol overdose drug complications primary nonfunction pnf indeterminate aetiology involved study randomly assigned either experimental control groups study found primary endpoint post admission mark increased survival rate bal patients control patients vs difference significant however patients pnf excluded results reduction mortality bal treated patients statistically significant advantage investigators noted exclusion pnf patients justifiable due early retransplantation lack intercranial hypertension hepatassist would give little benefit group secondary endpoint timetodeath patients alf known aetiology significant difference bal control groups bal patients surviving longer significant difference patients unknown aetiology however conclusions study suggest device potentially significant importance used treatment measure overall findings statistically significant aetiology patients taken account bal group gained statistically significant reduction mortality control group suggests device may applicable patients overall treatment liver dysfunction provide advantage heterogeneity patients considered used patients specific aetiology extracorporeal liver assist device elad humancell based treatment system catheter removes blood patient ultrafiltrate generator separates plasma rest blood plasma run separate circuit containing cartridges filled cells returned main circuit reentering thompson et performed large openlabel trial measuring effectiveness elad patients severe alcoholic hepatitis resulting aclf study involved patients screened sites across us uk australia enrolled total patients patients randomised either elad standard medical care groups even distribution patients terms sex meld score bilirubin levels patients elad group completed full hours treatment rest unable complete full regimen due variety reasons including withdrawal consent severe adverse events though completed hours treatment results showing minimal difference mortality receiving either hours full hours treatment study unable complete goal finding statistically significant improvement mortality rates patients received elad treatment receiving standard care days versus versus respectively biomarker measurements showed significantly reduced level bilirubin alkaline phosphatase elad patients though neither improvement translated increased survivability rates outcomes patients meld score decreased survivability elad patients presented raised creatinine kidney failure suggesting reason elad decreased survival chance standard care unlike artificial els devices hepatassist elad incorporate filtration devices charcoal columns exchange resins therefore replace filtration capability kidneys compensate multiorgan failure severe presentations aclf resulting increased mortality rates results study provide conclusive evidence suggest bal device like elad improves outcome severe aclf suggest aid survival patients less severe form disease patients meld beneficial effects seen weeks post treatment suggesting incorporating bal devices unable provide shortterm aid like artificial albumin filtration devices instead provide longterm aid recovery patient randomized phase trial elad device patients severe alcoholic hepatitis failed show benefit overall survival development artificial liver support systems aimed temporarily replace native liver detoxification functions use albumin scavenger molecule clear toxins involved physiopathology failing liver toxins accumulate plasma patients liver insufficiency protein bound therefore conventional renal dialysis techniques hemofiltration hemodialysis hemodiafiltration able adequately eliminate liver dialysis shown promise patients hepatorenal syndrome similar hemodialysis based principles hemodialysis remove toxins bound albumin accumulate liver failure like bioartificial liver device form artificial extracorporeal liver critical issue clinical syndrome liver failure accumulation toxins cleared failing liver based hypothesis removal lipophilic albuminbound substances bilirubin bile acids metabolites aromatic amino acids mediumchain fatty acids cytokines beneficial clinical course patient liver failure led development artificial filtration absorption devices liver dialysis performed physicians surgeons specialized nurses training gastroenterological medicine surgery namely hepatology alongside colleagues intensive critical care unit transplantation department responsible procuring implanting new liver part lobe one becomes available time patient eligible need experts well relative newness procedure certain areas usually available larger hospitals level trauma center teaching hospitals connected medical schools different albumin dialysis modalities single pass albumin dialysis spad shown positive results high proposed lowering concentration albumin dialysate seem affect detoxification capability nevertheless widely used systems today based hemodialysis adsorption systems use conventional dialysis methods albumin containing dialysate later regenerated means adsorption columns filled activated charcoal ion exchange resins present two artificial extracorporeal liver support systems molecular adsorbents recirculating system mars gambro fractionated plasma separation adsorption fpsa commercialised prometheus prom fresenius medical care two therapies mars frequently studied clinically used system date technique infancy prognosis patients liver failure remains guarded liver dialysis currently considered bridge transplantation liver regeneration case acute liver unlike kidney dialysis kidney failure support patient extended period time months years artificial detoxification devices currently clinical evaluation include single pass albumin dialysis spad molecular adsorbent recirculating system prometheus system dialive single pass albumin dialysis spad simple method albumin dialysis using standard renal replacement therapy machines without additional perfusion pump system patients blood flows circuit highflux hollow fiber hemodiafilter identical used mars system side membrane cleansed albumin solution counterdirectional flow discarded passing filter hemodialysis performed first circuit via highflux hollow fibers molecular adsorbents recirculation system mars best known extracorporal liver dialysis system consists two separate dialysis circuits first circuit consists human serum albumin contact patients blood semipermeable membrane two filters clean albumin absorbed toxins patients blood second circuit consists hemodialysis machine used clean albumin first circuit recirculated semipermeable membrane contact patients blood spad mars continuous venovenous haemodiafiltration cvvhdf compared vitro regard detoxification spad cvvhdf showed significantly greater reduction ammonia compared mars significant differences could observed spad mars cvvhdf concerning watersoluble substances however spad enabled significantly greater bilirubin reduction mars bilirubin serves important marker substance albuminbound nonwatersoluble substances concerning reduction bile acids significant differences spad mars seen concluded detoxification capacity spad similar even higher compared sophisticated complex hence expensive mars albumin dialysis costly procedure sevenhour treatment mars approximately ml human serum albumin solution mars treatment kit disposables used dialysis machine spent cost therapy adds approximately performing spad according protocol sauer et al however requires ml human albumin solution cost highflux dialyzer costing approximately tubings must also purchased overall costs spad treatment approximately costs equally efficient mars therapy session expenditure mars monitor necessary operate mars disposables included calculation prometheus system fresenius medical care bad homburg germany device based combination albumin adsorption highflux hemodialysis selective filtration albumin fraction specific polysulfon filter albuflow group eleven patients hepatorenal syndrome acuteonchronic liver failure accompanying kidney failure treatment two consecutive days four hours significantly improved serum levels conjugated bilirubin bile acids ammonia cholinesterase creatinine urea blood ph prometheus proven safe supportive therapy patients liver failure dialive yaqrit limited london uk incorporates albumin removal replacement endotoxin removal technology readiness level trl means validated disease mars developed group researchers university rostock germany later commercialized clinical use system able replace detoxification function liver minimizing inconvenience drawbacks previously used vivo preliminary investigations indicated ability system effectively remove bilirubin biliary salts free fatty acids tryptophan important physiological proteins albumin alpha antitrypsin transferrin globulin tyrosine hormonal systems also mars therapy conjunction crrthdf help clear cytokines acting inflammatory immunological mediators hepatocellular damage therefore create right environment favour hepatocellular regeneration recovery native liver function mars extracorporeal hemodialysis system composed three different circuits blood albumin lowflux dialysis blood circuit uses double lumen catheter conventional hemodialysis device pump patients blood mars flux biocompatible polysulfone highflux dialyser membrane surface area nm thickness cutoff kda marsflux essential retaining albumin dialysate blood dialysed human serum albumin hsa dialysate solution allows blood detoxification watersoluble proteinbound toxins means presence albumin dialysate albumin dialysis albumin dialysate regenerated close loop mars circuit passing fibres lowflux diaflux filter clear watersoluble toxins provide electrolyteacidbase balance standard dialysis fluid next albumin dialysate passes two different adsorption columns proteinbound substances removed diamars containing activated charcoal anionic substances removed diamars filled cholestyramine anionexchange resin albumin solution ready initiate another detoxifying cycle patients blood sustained adsorption columns saturated eliminating need continuously infuse albumin system treatment fig systematic review literature june performed following databases hepatic encephalopathy represents one serious extrahepatic complications associated liver neuropsychiatric manifestations affect consciousness behaviour evidence suggests develops neurotoxins neuro active substances produced hepatocellular breakdown accumulates brain consequence portosystemic shunt limited detoxification capability liver substances involved ammonia manganese aromatic aminoacids mercaptans phenols medium chain fatty acids bilirubin endogenous benzodiazepines etc relationship ammonia neurotoxicity first described animal studies pavlov et subsequently several studies either animals humans confirmed ratio ammonia concentration higher mm brain blood stream causes even comatose state value greater mm investigators also reported decrease serum ammonia following mars treatment table hourspatient μgdl μgdl manganese copper serum levels increased patients either acute acute chronic liver failure nevertheless patients chronic hepatic dysfunction bilateral magnetic resonance alteration globos pallidus probably type patients selectively shows higher cerebral membrane permeability imbalance aromatic branched chain aminoacids fischer index traditionally involved normalized following mars treatment effects noticeable even hours treatment reduction fisher index accompanied improvement novelli g et published three years experience mars analyzing impact treatment cerebral level patients reporting improvement glasgow coma score gcs observed patients last patients cerebral perfusion pressure monitored doppler mean flow velocity middle cerebral artery establishing clear relationship clinical improvement especially neurological improvement arterial cerebral perfusion study confirms results showing similar increments cerebral perfusion patients treated recently several studies shown significant improvement patients treated mars studies heemann et sen et improvement considered encephalopathy grade reduced one grades vs basal values hassenein et al randomized controlled trial improvement considered decrease two grades latter patients acute chronic liver failure encephalopathy grade iii iv included likewise kramer et estimated improvement improvement peak latency electroencephalograms observed sen et observed significant reduction childpugh score days following mars treatment without significant change controls nevertheless looked model endstage liver disease score meld significant reduction groups mars controls recorded respectively likewise several case series improvement grade mars therapy also hemodynamic instability often associated acute liver insufficiency consequence endogenous accumulation vasoactive agents blood characterized systemic vasodilatation decrease systemic vascular resistance arterial hypotension increase cardiac output gives rise hyperdynamic circulation mars therapy systemic vascular resistance index mean arterial pressure shown increase show schmidt et reported treatment patients diagnosed acute hepatic failure treated mars hours compared control group patients ice pads applied match heat loss produced treatment group extracorporeal therapy analyzed hemodynamic parameters groups hourly mars group statistically significant increase systemic vascular resistance observed dinas x x x compared increase controls mean arterial pressure also increased mmhg p mars group whereas difference observed controls cardiac output heart rate also decreased mars group consequence improvement hyperdynamic circulation therefore shown statistically significant improvement obtained mars compared smt catalina et also evaluated systemic hepatic hemodynamic changes produced mars therapy patients acute decompensation chronic liver disease observed mars therapy attenuation hyperdynamic circulation reduction portal pressure gradient measured results summarized table studies also worth mentioning similar results heemann et parés et among others dethloff et concluded statistically significant improvement favourable mars comparison prometheus system table hepatorenal syndrome one serious complications patients acute decompensation cirrhosis increased portal hypertension characterized hemodynamic changes splanchnic systemic renal circulation splanchnic vasodilatation triggers production endogenous vasoactive substances produce renal vasoconstriction low glomerular filtration rate leading oliguria concomitant reduction creatinine clearance renal insufficiency always progressive inferior survival months respectively pierre one pioneers study hepatorenal syndrome patients liver impairment great efforts made trying improve prognosis type patient however solved problem orthotopic liver transplantation treatment shown improve acute chronic complications derived severe liver insufficiency today possible combine albumin dialysis continuous venovenous hemodialfiltration provides greater expectation optimization clinical status mars treatment lowers serum urea creatinine levels improving even favors resolution hepatorenal results confirmed randomized controlled trial published mitzner et patients diagnosed hepatorenal syndrome type treated mars therapy mean survival days mars group compared days observed controls hemodiafiltration standard care smt applied resulted statistically significance difference survival days authors concluded mars therapy applied liver failure patients childpugh c unos scores develop hepatorenal syndrome type prolonged survival compared patients treated smt although mechanisms explaining previous findings yet fully understood reported decrease plasma renin concentrations patients diagnosed acute chronic liver failure renal impairment treated mars likewise studies suggested efficacy mars treatment hepatorenal however references published show efficacy treatment types patients mars therapy khuroo et published metaanalysis based small rcts non rcts patients diagnosed aclf concluding mars therapy would bring significant increment survival compared smt another observational study patients cirrhosis refractory ascites hepatorenal syndrome type responding vasoconstrictor therapy showed impact hemodynamics following mars therapy however authors concluded mars therapy could effectively serve bridge liver total bilirubin parameter analyzed trials always reduced groups patients treated mars banayosy et measured bilirubin levels days since mars therapy terminated observed consistent significant decrease bilirubin also creatinine urea table sessions impact mars therapy plasma biliary acids levels evaluated studies study stadbauer et specifically addressing topic reported mars prometheus systems lower extent biliary acids plasma concentration heemann et laleman et also published significant improvement organic ions pruritus one common clinical manifestations cholestasis liver diseases one distressing symptoms patients chronic liver disease caused viral hepatitis c many hypotheses formulated explain physio pathogenesis manifestation including incremental plasma concentration biliary acids abnormalities bile increased central neurotransmitters coupling opioid etc despite number historical drugs used individually combined exchange resins hydrophilic biliary acids antihistamines antibiotics anticonvulsants opioid antagonists reported cases intractable refractory pruritus dramatic reduction patients quality life ie sleep disorders depression suicide intractable pruritus indication liver transplantation mars indication intractable pruritus therapeutically option shown beneficial patients desperate cases although high several studies confirmed mars treatments patients remain free pruritus period time ranging nevertheless authors concluded besides good results found literature application mars therapy refractory pruritus requires larger pharmacokinetics pharmacodynamics majority drugs significantly modified liver failure affecting therapeutic approach potential toxicity drugs type patients childpugh score represents poor prognostic factor assess metabolic capacity failing liver patients hepatic failure drugs metabolized liver accumulate plasma right administered therefore needed modify drug dosing concentration time intervals lower risk toxicity also necessary adjust dosing drugs exclusively metabolized liver low affinity prioteins high distribution volume fluoroquinolones levofloxacin extracorporeal detoxification albumin dialysis increases clearance drugs bound plasmatic proteins table metaanalysis published khuroo et included randomized improvement survival patients liver failure treated mars compared smt observed however neither extracorporeal liver support systems review published metaanalysis kjaergard et significance difference survival found patients diagnosed alf treated extracorporeal liver support systems nevertheless reviews included kind liver support systems used heterogeneous type publication abstracts clinical trials cohort etc literature showing favorable results survival patients diagnosed alf treated mars randomized controlled trial salibà et studied impact survival mars therapy patients alf waiting liver transplant list fortynine patients received smt treated mars observed patients received mars sessions showed statistically significance increase transplantfree survival compared others patients study notably patients underwent liver transplantation first hours inclusion waiting list besides short exposure mars therapy patients showed better survival trend compared controls treated mars prior transplant casecontrolled study montejo et reported mars treatment decrease mortality directly however treatment contributed significantly improve survival patients transplanted studies mitzner et heemann et able show significance statistical difference survival patients mars group however el banayosy et hassanein et noticed non significant improvement survival probably short number patients included trials majority available mars studies published patients diagnosed alf either transplanted survival greater mars group variations according type trial ranging data summarized tables mars controls patients diagnosed acute chronic liver failure treated mars therapy clinical trial results showed statistically significant reduction mortality odds ratio confident interval ci p figure nonstatistically significant reduction mortality shown patients alf treated mars ci p figure combined results yielded nonsignificant reduction mortality patients treated mars therapy however low number patients included studies may responsible able achieve enough statistical power show differences treatment groups moreover heterogeneity number mars sessions severity liver disease patients included make difficult evaluation mars impact survival recently metaanalysis survival patients treated extrahepatic therapy searching strategies yielded clinical trials randomized controlled trials case control cohort studies eight studies included metaanalysis three addressing acute liver failure one mars five addressing acute chronic four mars authors concluded extrahepatic detoxifying systems improve survival acute liver insufficiency whereas results acute decompensation chronic liver diseases suggested non significant survival benefit also due increased demand liver transplantation together augmented risk liver failure following large resections development detoxifying extrahepatic systems necessary safety defined presence adverse events evaluated trials adverse events patients receiving mars therapy similar controls exception thrombocytopenia hemorrhage seems occur frequently mars heemann et reported two adverse events probably mars related fever sepsis presumably originated catheter study hassanein et two patients mars group abandoned study owing hemodynamic instability three patients required larger average platelets transfusion three patients presented gastrointestinal bleeding laleman et detected one patient thrombocytopenia mars prometheus treatment groups additional patient clotting dialysis circuit hypotension prometheus group kramer et al wrote cases disseminated intravascular coagulation interventional group two fatal outcomes mitzner et described among patients treated mars thrombocytopenia case second patient chronic hepatitis b underwent tips placement day randomization died day multiorgan failure consequence complications related tips procedure montejo et showed mars easy technique without serious adverse events related procedure also easy implement icu settings used renal extracorporeal therapies mars international registry data patients although sponsored manufacturer shows adverse effects observed similar control group however severely ill patients difficult distinguish complications disease side effects attributable technique three studies addressing costeffectivenenss mars therapy found hassanein et analysed costs randomized patients aclf receiving mars therapy standard medical care used study published kim et describing impact complications hospitalization costs patients diagnosed alcoholic liver failure cost patients treated standard medical care smt compared received mars addition smt patients mars group less inhospital mortality complications related disease remarkable reduction cost compensated mars related expenditure table survivors control group cost per patient whereas mars group patients survived cost per patient represents savings per patient favors mars group hessel et published followup cohort patients aclf received mars treatments received smt survival mars group controls reduced respectively one year followup three years hospitalization costs mars treated group greater controls vs similarly direct cost followup vs nevertheless adjusting mortality rate annual cost per patient controls mars group also latter found incremental costeffectiveness ratio per lifeyear gained lyg incremental costs per qaly gained two years later authors published results patients diagnosed patients treated mars patients allocated receive smt mean survival time days mars group years days controls years results significant differences average cost ic mars patients control group incremental cost per lyg ic ic per qualityadjusted life years qaly liver support systems mars important stabilize patients acute acute chronic liver failure avoid organ dysfunction well bridgetotransplant although initial inhospital costs high worth favorable outcome etiology goals mars therapy mars therapy indication treatment schedule etiology goals mars therapy mars therapy indication treatment schedule etiology goals mars therapy mars therapy indication treatment schedule etiology goals mars therapy mars therapy indication treatment schedule etiology goals mars therapy mars therapy indication treatment schedule contraindications extracorporeal treatment may applied mars therapy blood flow trend use high flow rates although determined technical specifications combined machine catheters size intermittent treatments continuous treatments dyalisate flow rate intermittent treatments continuous treatments replacement flow rate heparin anticoagulation similarly cvvhd depends previous patients coagulation status many cases needed unless patient presents ptt inferior seconds patients normal values bolus iu heparin could administered commencement treatment followed continuous perfusion keep ptt ratios seconds monitoring biochemical analysis recommended liver kidney profile ionic glucose together hemogram end first session starting following one coagulation analysis must also performed starting session adjusting heparin dose case medication susceptible eliminated mars administered also recommended monitor levels blood end session catheters lumens heparinized federal drug administration fda cleared document dated may mars therapy treatment drug overdose poisoning requirement drug poison must susceptible dialysed removed activated charcoal anionic exchange resins recently december mars therapy cleared fda treatment hepatic encephalopathy due decompensation chronic liver disease clinical trials conducted mars treatment patients decompensation chronic liver disease demonstrated transient effect mars treatments significantly decrease hepatic encephalopathy scores least grades compared standard medical therapy smt mars indicated bridge liver transplant safety efficacy demonstrated controlled randomized clinical trials effectiveness mars device patients sedated could established clinical studies therefore predicted sedated patients livernet database dedicated liver diseases treated support extracorporeal therapies date currently used system molecular adsorbent recirculating system mars based selective removal albumin bound molecules toxins blood patients acute acuteonchronic liver failure purpose register prospectively patients treated worldwide mars system order livernet ecrf database wwwlivernetnet using sas platform allows major advantages centres including automatic calculations liver rand icu scoring systems instant queries online instant export patients included database centre excel file direct statistical analysis finally instant online statistical analysis selective data decided scientific committee therefore livernet important tool progress knowledge liver support therapies httpsenwikipediaorgwikiliverdialysis